Johnson & Johnson (JNJ) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Johnson & Johnson (NYSE: JNJ):

• 8/6/2026 – Johnson & Johnson had its price target raised by Guggenheim from $270.00 to $287.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Johnson & Johnson was given a new $280.00 price target by Raymond James Financial, Inc..
• 8/3/2026 – Johnson & Johnson had its “buy” rating reaffirmed by Johnson Rice.
• 8/3/2026 – Johnson & Johnson had its price target raised by Wells Fargo & Company from $272.00 to $282.00. They now have an “overweight” rating on the stock.
• 8/1/2026 – Johnson & Johnson was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/29/2026 – Johnson & Johnson was given a new $300.00 price target by Argus.
• 7/24/2026 – Johnson & Johnson was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 7/18/2026 – Johnson & Johnson was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/17/2026 – Johnson & Johnson had its “buy” rating reaffirmed by Guggenheim. They now have a $270.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson was upgraded by Johnson Rice from “outperform” to “buy”. They now have a $280.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson had its “outperform” rating reaffirmed by Scotiabank. They now have a $305.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson had its price target raised by Raymond James Financial, Inc. from $258.00 to $265.00. They now have an “outperform” rating on the stock.
• 7/16/2026 – Johnson & Johnson was given a new $261.00 price target by Johnson Rice.
• 7/16/2026 – Johnson & Johnson had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $282.00 price target on the stock.
• 7/16/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $284.00 to $294.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – Johnson & Johnson had its price target raised by Wells Fargo & Company from $263.00 to $272.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – Johnson & Johnson was upgraded by Freedom Capital from “hold” to “strong-buy”.
• 7/15/2026 – Johnson & Johnson was given a new $260.00 price target by Stifel Nicolaus.
• 7/13/2026 – Johnson & Johnson had its price target raised by TD Cowen from $250.00 to $300.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Johnson & Johnson had its price target raised by Royal Bank Of Canada from $265.00 to $287.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Johnson & Johnson had its price target raised by Bank of America Corporation from $254.00 to $263.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $283.00 to $284.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $285.00 to $298.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Johnson & Johnson was given a new $290.00 price target by HSBC Holdings plc. They now have a “buy” rating on the stock.
• 6/26/2026 – Johnson & Johnson was given a new $270.00 price target by Johnson Rice.
• 6/26/2026 – Johnson & Johnson had its price target raised by Guggenheim from $266.00 to $270.00. They now have a “buy” rating on the stock.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 48,972 shares of company stock valued at $12,295,205. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.